Floatz logo

Ny-Eso-1 157-165

Glioblastoma

Adilia HormigovaccinePhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

233 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
Lomustine
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3BB
Enzastaurin
Denovo Biopharma LLC
Phase 3BB
Inno-206
Université de Sherbrooke
Phase 2BB

View all 50 →

Same molecule, other indications

Ny-Eso-1 157-165 is also rated in:

MelanomaDormant
CC
Indicative ·
44 / 100
View asset →
Solid TumorsDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →